Home » Topics » BioWorld Science, Nephrology

BioWorld Science, Nephrology
RSS

Taisho presents new compounds with potential in the treatment of renal and cardiovascular conditions

Dec. 22, 2000

Vivus granted third PDE inhibitor patent

Dec. 21, 2000

Cialis shows promise as ED therapy in phase II

Dec. 19, 2000

Imidazoline alpha1A-adrenoceptor agonists especially useful in Rx of urinary incontinence

Dec. 7, 2000

Yamanouchi discovers novel class of potent, nonsteroidal human 5alpha-reductase inhibitors

Nov. 29, 2000

R&D at Sanofi-Synthelabo leads to identification of potent PDE5 inhibitors

Nov. 27, 2000

Novel steroidal aromatase inhibitor TZA-2237 tested in dog models of BPH

Nov. 27, 2000

Sildenafil tested in patients with LVD

Nov. 24, 2000

Potential new treatments for urinary incontinence described by Sanofi-Synthelabo

Nov. 20, 2000

Triarylimidazoles synthesized at SmithKline Beecham active as inhibitors of TGF-beta signaling

Nov. 20, 2000

Popular Stories

Today's news in brief
BioWorld
First-in-class pan-inflammasome blocker for hidradenitis suppurativa
BioWorld Science
Researchers from Paratus Sciences Corp. presented the preclinical profile of PS-1001, a novel pan-inflammasome inhibitor designed to prevent IL-1β and IL-18 release.
SCAN is core circuit affected in Parkinson’s disease
BioWorld
Parkinson’s disease is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder, and...
RX-10616 improves radiotherapy efficacy in HNSCC
BioWorld Science
Head and neck squamous cell carcinoma (HNSCC) accounts for high number of new diagnoses each year. Current management is based on surgery followed by radiotherapy...
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...